Mitoxantrone Completed Phase 2 Trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Monoblastic Leukemia (M5a) / Adult Erythroleukemia (M6a) / Untreated Adult Acute Myeloid Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Pure Erythroid Leukemia (M6b) / Adult Acute Myeloid Leukemia With Del(5q) / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloblastic Leukemia With Maturation (M2) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00795002Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01349972Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia